Fondazione Policlinico Universitario Agostino Gemelli IRCCS: Breast Neoplasms trials

The registry lists 30 Breast Neoplasms studies with Fondazione Policlinico Universitario Agostino Gemelli IRCCS as lead sponsor. 16 are open to participants now and 0 have results posted.

No phase 30(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Artificial Intelligence Integration in Breast Cancer Screening: The ANIHTA StudyNot yet recruitingNCT07879937
• A Master Regulator of Lipid-Associated Macrophage Function in CancerNot yet recruitingNCT07848061
• Tumor Integrating Gut Microbiota in bREast CancerNot yet recruitingNCT07253168Not applicable
• Development of a New Remote Monitoring Model for Patients With HR+HER2- Breast Cancer in Treatment With CDK4/6 Inhibitors and Hormone TherapyNot yet recruitingNCT07190651
• Clinical Validation of Sophia Genetics AssayNot yet recruitingNCT07160010
• EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly PhaseRecruitingNCT06894173
• Psychological Well-being in Patients With Breast CancerRecruitingNCT06590727
• Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.RecruitingNCT06441240
• New Digital Person-based Care Model in Patients With HER2-negative Advanced Breast CancerNot yet recruitingNCT06348654
• Breast Cancer Subtype Characterization Through Patient's Derived Organoids.RecruitingNCT06315868
• Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic SyndromeRecruitingNCT06261918
• Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast CancerRecruitingNCT06243432
• Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant ChemotherapyNot yet recruitingNCT06131632Not applicable
• Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational StudyRecruitingNCT06093022
• Treatment of Insomnia in Patients With Breast CancerRecruitingNCT06061666Not applicable
• New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast CancerRecruitingNCT05893368
• Selective Axillary Dissection After Neoadjuvant Chemotherap Yin Patients With Lymphnode-positive Breast CancerCompletedNCT07828925
• An Integrated Genomic Approach to Assess Genetic Risk and Drug SensitivityActive, not recruitingNCT07555639Not applicable
• Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) StudyActive, not recruitingNCT07008508
• Transgender and Gender Diverse Individuals Screening for Breast CancerActive, not recruitingNCT06347393Not applicable
• Lipidomic Characterization in Non-metastatic Breast Cancer Women Undergoing Surgery: a Pilot Study.Active, not recruitingNCT06026631Not applicable
• Evaluating Breast Cancer Patients Modesty During Radiotherapy. A Multicentric StudyCompletedNCT05808569
• Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic EvaluationStatus unknownNCT05763472
• Acupuncture Treatment of Vasomotor Symptoms in Breast Cancer PatientsStatus unknownNCT05760222Not applicable
• BRCA and NACT in TNBC PatientsCompletedNCT05750719
• PIK3CA in HER2+ BC and pCR TrialStatus unknownNCT05750693Not applicable
• Endocrine Disruptors and Life STILe in Breast Cancer DevelopmentStatus unknownNCT05748353
• Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast CancerCompletedNCT05609903
• The Immersive Experience of Virtual Reality During Chemotherapy in Patients With Early Breast and Gynecological Cancers: the Patient's Dream StudyCompletedNCT05234996Not applicable
• Innovative "Scoring System" in Breast Cancer Post Neoadiuvant ChemotherapyCompletedNCT05213403